产品
编 号：F745331
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1450981-87-9
产品详情
生物活性：
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time.
体内研究：
Letolizumab 抑制 CD40L 三聚体和 CHO-CD40L 在人类 B 细胞 (IC50 值分别为 3.6 nM 和 1.3 nM) 或非人类灵长类 B 细胞 (IC50 值分别为 3.8 nM 和 7.3 nM) 中的活力。Letolizumab (2、10 和 20 mg/kg；静脉注射；一周一次持续 10 周) 延长了肾移植后的恒河猴的存活时间。Animal Model:Rhesus macaques after renal transplantation.
Dosage:2, 10 and 20 mg/kg.
Administration:Intravenous injection; once a week for 10 weeks.
Result:Increased the survival time.
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time.
体内研究：
Letolizumab 抑制 CD40L 三聚体和 CHO-CD40L 在人类 B 细胞 (IC50 值分别为 3.6 nM 和 1.3 nM) 或非人类灵长类 B 细胞 (IC50 值分别为 3.8 nM 和 7.3 nM) 中的活力。Letolizumab (2、10 和 20 mg/kg；静脉注射；一周一次持续 10 周) 延长了肾移植后的恒河猴的存活时间。Animal Model:Rhesus macaques after renal transplantation.
Dosage:2, 10 and 20 mg/kg.
Administration:Intravenous injection; once a week for 10 weeks.
Result:Increased the survival time.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备